source
- J&J strikes up to $925M deal with Sail Biomedicines, secures option to buy for $2.58BJohnson & Johnson announced a collaboration with Flagship Pioneering’s Sail Biomedicines to develop in vivo CAR‑T therapies for immune‑mediated diseases. The agreement provides up to $925 million i…
- Ebola cases approach key milestone as vaccine candidates draw near completionThe latest update on the Ebola outbreak indicates that the number of cases is approaching a significant threshold, while vaccine development efforts are reported to be close to delivering a usable…